Podcast profile
By Labiotech
Welcome to the official Labiotech podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world.
Latest episode
40 min
Topics
Biological research, therapeutics, diagnostics, genomics, and biotechnology companies.
Connected devices, sensors, edge systems, device platforms, and IoT operations.
Company formation, founding, product-market fit, scaling, and startup operations.
Formats
Host-led conversation where a guest supplies most of the subject matter.
Interpretation, opinion, debate, review, and analytical discussion.
Audience level
Assumes basic technology literacy and familiarity with common products, roles, and terminology.
Stay connected
From the feed
Episodes shown — 10 of 25
Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months.
Most genetic medicines are built to treat one gene, one mutation, one disease at a time. That's true even for the newest modalities — gene therapy, gene editing, mRNA — each still has to be engineered disease by disease.
Gene therapy has largely stayed out of the brain, and the blood-brain barrier has been the reason why — it protects the brain from harm, but it also blocks most advanced medicines from ever reaching it. That's now beginning to change.
Today we’re thrilled to bring you a special episode highlighting one of Europe’s premier biotechnology events: BIOSPAIN 2026. Joining us is Stuart Medina of Asebio, who will take us inside this landmark gathering.
What if the key to beating cancer wasn't a new drug, but a new way of thinking about matter itself? That's the question Laurent Lévy asked when he co-founded Nanobiotix over twenty years ago — and it's a question that is now producing some genuinely compelling answers in the clinic.
Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive.
RNA therapeutics has had its defining moments. Antisense oligonucleotides. siRNA. And then, of course, mRNA — which went from a niche academic curiosity to the backbone of a global vaccine program in a matter of months. The next chapter may be circular RNA.
Today we welcome Gene Mack, President and CEO of Gain Therapeutics. With over 25 years of experience spanning biochemistry, Wall Street analysis, and biotech leadership, Gene brings deep expertise in capital markets, strategy, and drug development. He joined Gain in 2024 and stepped into the CEO role in early 2025.
Epidermolysis bullosa, or EB, is one of those diseases that stops you in your tracks the moment you understand it. Skin so fragile that the gentlest touch can cause blisters and open wounds. No cure. And for most of its history, very little serious drug development attention. That's where today's guest comes in.
The life sciences industry has always had one great meeting place, a few days in November where the deals get done, the partnerships form, and the direction of the industry quietly shifts. For more than three decades, that place has been BIO-Europe. But this year, something is changing.